Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate
The recent SARS-CoV-2 (COVID-19) pandemic exemplifies how newly emerging and reemerging viruses can quickly overwhelm and cripple global infrastructures. Coupled with synergistic factors such as increasing population densities, the constant and massive mobility of people across geographical areas an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/11/1201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850147043387899904 |
|---|---|
| author | Alexis Catala Bennett J. Davenport Thomas E. Morrison Carlos E. Catalano |
| author_facet | Alexis Catala Bennett J. Davenport Thomas E. Morrison Carlos E. Catalano |
| author_sort | Alexis Catala |
| collection | DOAJ |
| description | The recent SARS-CoV-2 (COVID-19) pandemic exemplifies how newly emerging and reemerging viruses can quickly overwhelm and cripple global infrastructures. Coupled with synergistic factors such as increasing population densities, the constant and massive mobility of people across geographical areas and substantial changes to ecosystems worldwide, these pathogens pose serious health concerns on a global scale. Vaccines form an indispensable defense, serving to control and mitigate the impact of devastating outbreaks and pandemics. Towards these efforts, we developed a tunable vaccine platform that can be engineered to simultaneously display multiple viral antigens. Here, we describe a second-generation version wherein chimeric proteins derived from SARS-CoV-2 and bacteriophage lambda are engineered and used to decorate phage-like particles with defined surface densities and retention of antigenicity. This streamlines the engineering of particle decoration, thus improving the overall manufacturing potential of the system. In a prime-boost regimen, mice immunized with particles containing as little as 42 copies of the chimeric protein on their surface develop potent neutralizing antibody responses, and immunization protects mice against virulent SARS-CoV-2 challenge. The platform is highly versatile, making it a promising strategy to rapidly develop vaccines against a potentially broad range of infectious diseases. |
| format | Article |
| id | doaj-art-7e49fa4be0f44228a3dade85006b2ea5 |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-7e49fa4be0f44228a3dade85006b2ea52025-08-20T02:27:41ZengMDPI AGVaccines2076-393X2024-10-011211120110.3390/vaccines12111201Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine CandidateAlexis Catala0Bennett J. Davenport1Thomas E. Morrison2Carlos E. Catalano3Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USADepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USADepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USADepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USAThe recent SARS-CoV-2 (COVID-19) pandemic exemplifies how newly emerging and reemerging viruses can quickly overwhelm and cripple global infrastructures. Coupled with synergistic factors such as increasing population densities, the constant and massive mobility of people across geographical areas and substantial changes to ecosystems worldwide, these pathogens pose serious health concerns on a global scale. Vaccines form an indispensable defense, serving to control and mitigate the impact of devastating outbreaks and pandemics. Towards these efforts, we developed a tunable vaccine platform that can be engineered to simultaneously display multiple viral antigens. Here, we describe a second-generation version wherein chimeric proteins derived from SARS-CoV-2 and bacteriophage lambda are engineered and used to decorate phage-like particles with defined surface densities and retention of antigenicity. This streamlines the engineering of particle decoration, thus improving the overall manufacturing potential of the system. In a prime-boost regimen, mice immunized with particles containing as little as 42 copies of the chimeric protein on their surface develop potent neutralizing antibody responses, and immunization protects mice against virulent SARS-CoV-2 challenge. The platform is highly versatile, making it a promising strategy to rapidly develop vaccines against a potentially broad range of infectious diseases.https://www.mdpi.com/2076-393X/12/11/1201phage-like particlesviral nanoparticlesvaccine developmentSARS-CoV-2nanomedicine |
| spellingShingle | Alexis Catala Bennett J. Davenport Thomas E. Morrison Carlos E. Catalano Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate Vaccines phage-like particles viral nanoparticles vaccine development SARS-CoV-2 nanomedicine |
| title | Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate |
| title_full | Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate |
| title_fullStr | Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate |
| title_full_unstemmed | Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate |
| title_short | Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate |
| title_sort | second generation phage lambda platform employing sars cov 2 fusion proteins as a vaccine candidate |
| topic | phage-like particles viral nanoparticles vaccine development SARS-CoV-2 nanomedicine |
| url | https://www.mdpi.com/2076-393X/12/11/1201 |
| work_keys_str_mv | AT alexiscatala secondgenerationphagelambdaplatformemployingsarscov2fusionproteinsasavaccinecandidate AT bennettjdavenport secondgenerationphagelambdaplatformemployingsarscov2fusionproteinsasavaccinecandidate AT thomasemorrison secondgenerationphagelambdaplatformemployingsarscov2fusionproteinsasavaccinecandidate AT carlosecatalano secondgenerationphagelambdaplatformemployingsarscov2fusionproteinsasavaccinecandidate |